

**University of Washington  
Pharmaceutical Outcomes Research and Policy Program**

**Annual Update  
Fall 2006**



**Graduation, June 2005**

L to R: B.Devine, L.Garrison, J.Gardner, S.Sullivan,  
Graduate: Scott Strassels, Ph.D., T.Hazlet, D.Veenstra

**New Faculty, Recent Graduates & New Students**

**New Faculty**

**Srikanth Kadiyala, PhD**

Srikanth joins us from the Harvard School of Public Health, where he has just completed his PhD in Health Policy (Economics track). His dissertation work covered two broad areas of study. First, he examined the effects of the incidence of cancer in the family on the demand for cancer screenings and health insurance. His second area of study compared the impact of the type of health insurance (managed care versus fee-for-service) on the quality of patient care. As a member of the PORPP faculty Srikanth plans to continue his work in the areas of quality, managed care and insurance markets. He will also be looking at the impact of guidelines on the quality of physician care in cancer screenings. He will participate in teaching health economics and policy courses. Srikanth received his BA in Economics from the University of Chicago, and has served as a research assistant at the National Bureau of Economic Research.

**Congratulations to Recent Graduates**

**Thy Do, MS, MPH, PhD**

*“Outpatient Discontinuation of Post-Myocardial Infarction Beta-Blocker Therapy and Its Effect on Recurrent Coronary Events”*. Dr. Do is with the Epidemiology Group at Amgen Pharmaceuticals in San Francisco, CA.

**Nina Oestreicher, MS, PhD**

*“Cost-effectiveness of DNA Microarray Analysis in Women with Early Stage Breast Cancer”*. Dr. Oestreicher is employed as a research scientist with Kaiser Permanente Northern California, Division of Research.

**Scott Strassels, PharmD, PhD**

*“The Economics and Epidemiology of Pain in Persons Receiving Hospice Care”*. Dr. Strassels is an Assistant Professor at the College of Pharmacy, University of Texas, Austin.

## .....and New Graduate Students

### **Joseph Brian Babigumira, MBChB, MS**

Joseph joins us from Case Western Reserve University, where he has just completed his MS in Health Services Research, having been awarded the International Clinical, Operational, and Health Services Research and Training Award of the Fogarty International Center at the NIH. He is a physician graduate of the Mbarara University of Science and Technology, where he received his Bachelor of Medicine and Surgery (MBChB), and the Ntare School, Mbarara, Uganda. Joseph brings to the PORPP PhD program his experience as a physician, teacher and lecturer. He has conducted work in *falciparum malaria* and HIV. His long-term goal is to conduct cost-effectiveness research and to influence health policy in Uganda and other sub-Saharan countries.

### **Mindy Cheng, BS, MS**

Mindy received her BS in Microbiology from the University of Michigan and her MS in Healthcare Administration from the California State University, East Bay. She joins us from the ALZA Corporation, Mountain View, California, where she has been employed as both a microbiologist and a regulatory affairs associate. Through her training and employment, Mindy has honed her interest in developing and evaluating health policies that will bring pharmaceutical innovations to the developing world. Mindy is enrolled in the PhD program.

### **Catherine Wairimu Waweru, BSc, MSc**

Catherine has trained as a pharmacist, receiving her BSc in Pharmacy from the University of Nairobi, Kenya, and her MSc in Clinical Pharmacy, International Practice and Policy from the University of London. Catherine has served as the Chief Pharmacist in a government hospital in Kenya, where she developed a program that ensured the availability of essential drugs at a reasonable cost to patients. It was through this innovative and successful endeavor that she was awarded a scholarship to study in London. It was also through this experience that Catherine developed her desire to receive formal training in policy research. After completion of the PORPP PhD program Catherine intends to pursue a career as a policy-maker in Kenya, creating policies that will improve access to necessary pharmaceuticals and health services for the people of Kenya – particularly women and children.

### **Jelena Zurovac, BA**

Jelena is joining the PORPP program to pursue an MS in Pharmaceutical Outcomes. She is currently a PhD student in the Department of Economics, UW. Jelena completed her BA in Economics at Smith College and has served as a research assistant at Smith, where she studied the historical and empirical relationship between income inequality and economic growth. Through this experience she developed an interest in privatization in transition economies, specifically its effect on the populations that it affects. Jelena also has experience as an intern-analyst with Morgan Stanley, as a conversation partner in Serbo-Croatian with the Five College Self-Instructional Language Program in Amherst, MA, and as an assistant manager with Norwegian People's Aid in Igalo/Podgorica, Montenegro.

## Visiting Scholar

### **Sang-Eun Choi, PhD**

Dr. Sang-Eun Choi, is Senior Researcher, Health Insurance Review Agency, Seoul, Korea. Dr. Choi received her PhD degree in Health Policy and Administration. Dr. Choi's fellowship at UW was sponsored by the Korea Science and Engineering Foundation (KOSEF). The KOSEF sponsors overseas post-doctoral fellowship programs for Korean scientists, enabling them to become familiar with state-of-the-art scientific knowledge in advanced countries. While at UW Dr. Choi studied with Dr. Sean Sullivan. She focused her work in three areas: the selection and measurement of health outcomes, the modeling techniques used in economic evaluations, and the policies surrounding the use of economic evaluations of pharmaceuticals, in the context of formulary decision-making. Dr. Choi has now returned to Korea and is employing the tools for economic evaluation into the formulary decision-making process in the Korean Health Insurance Review Agency.

## Promotions

**Scott Ramsey, MD, PhD** has been promoted to Full Professor.

**David Veenstra, PharmD, PhD** has been promoted to Associate Professor.

## Honors and Awards

### **Faculty**

**David Au** - Advanced Research Career Development Award, Veterans Affairs Administration; Early Career Achievement Award, Behavioral Sciences Assembly of the American Thoracic Society

**Beth Devine** - Mentored Clinical Scientist Training Award, Agency for Healthcare Research and Quality

**Lou Garrison**- Presentations to the Institute of Medicine 1) "Forum on Drug Discovery, Development, and Translation: Understanding the Benefits and Risks of Pharmaceuticals" 2) Committee on the Assessment of the US Drug Safety System

**Tom Hazlet** - Honorable Mention for the Excellence in Teaching Award, University of Washington Educational Outreach Program

**Will Hollingworth** - Mentorship / Teaching Award, Robert Wood Johnson Clinical Scholars Program; "Editor's Recognition Award for Reviewing with Distinction", *Radiology*

**Todd Lee** - Center Director's Award, Midwest Center for Health Services and Policy Research, Hines Veterans Affairs Administration

**Scott Ramsey** has been elected to membership in the American Society for Clinical Investigation, a 98-year-old, 2,800 physician-scientist member medical honor society that elects fewer than eighty new members per year, who have (by the age of 45 years) have made significant accomplishments within their field.

**Andy Stergachis** - Visiting Professor, University of Crete Medical School, Heraklion, Crete; member, Committee on the Assessment of the US Drug Safety System, Institute of Medicine;

currently on sabbatical at the Infectious Diseases Institute, Makerere University, Kampala, Uganda

**David Veenstra** - "Recognition for Highest Quality Peer Review", *Journal of Managed Care Pharmacy*; member, Institute of Medicine Committee on "Genomics and the Public's Health in the 21st Century"

### Students

**Joseph Babigumira**, - International Clinical, Operational, and Health Services Research and Training Award (OCOHSRTA), Fogarty International Center, National Institutes of Health

**Jonathan Campbell** – predoctoral fellowships, Genentech and Novartis

**James Cross** – predoctoral fellow, UW Biobehavioral Cancer Prevention and Control Training Program, National Cancer Institute

**Elizabeth James**- current recipient of the UW Warren G. Magnuson Scholar Award for 2006-2007. Along with her faculty mentor, **Dr. Tom Hazlet**, she is one of 35 scholarship recipient pairs, nationwide, to receive a 2006 Wal-Mart Annual Conference Travel Scholarship to the AACP Teachers Seminar in San Diego.

**Matthew Kerrigan** - affiliate fellow, UW Biobehavioral Cancer Prevention and Control Training Program, National Cancer Institute

**Lisa Meckley** – predoctoral fellowship in Outcomes Research, PhRMA Foundation; Best Student Podium Presentation, 9<sup>th</sup> Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research

**Sarika Ogale** - UW Warren G. Magnuson Scholar Award

**Eldon Spackman** - pre-doctoral fellowship, Eli Lilly

**Catherine Waweru** – post-graduate fellowship, Commonwealth Scholarship, UK

**Brian Bresnahan** - post-doctoral fellowship, Eli Lilly

### Current Research

- **David Au** and **Todd Lee** are investigating outcomes associated with salmeterol use in obstructive lung disease; Dr. Au is also investigating how to improve health outcomes for patients with chronic obstructive pulmonary disease.
- **Denise Boudreau** is currently investigating the association between HMG-CoA Reductase inhibitors (statins) and other medications and risk of development of site-specific cancers. She is also determining the economic burden of metabolic syndrome and, separately, the extent of prescription opioid misuse in a large HMO.
- **Dave Blough**, **Sean Sullivan** and **Scott Ramsey** are calculating the expected value of population

information and the expected value of sample information to determine the benefit of conducting additional clinical trials evaluating long-volume reduction surgery for severe emphysema.

- **Rick Carlson**, with **Lou Garrison** and **Dave Veenstra** is developing a primer on the economic implications of pharmacogenomics for pharmaceutical manufacturers, health care payers and systems, providers and patients.
- **Brian Custer** has just completed a study that determined the cost-effectiveness of screening the US blood supply for West Nile virus. He has also developed a model to assess the safety of the community blood supply.
- **Beth Devine**, **Will Hollingworth** and **Sean Sullivan** are evaluating the impact of an electronic prescribing system on medication safety and on process outcomes within an ambulatory health-system. Dr. Devine is also exploring the relationship between prescriber attributes and the adoption of this information technology.
- **Jacqueline Gardner** is evaluating community pharmacists' interventions to increase access to public health services, such as immunizations, and contraception.
- **Lou Garrison** is studying the scientific and economic challenges in linking pharmacogenetics-based diagnostics and pharmaceuticals for personalized medicine. He is also evaluating the use of integrative models of long-term health outcomes and the use of utility measurement as methods of explicit and quantitative processes for assessing benefit-risk balance at various stages of drug marketing.
- **Tom Hazlet** is assessing the longitudinal impact on health outcomes of annual changes to a pharmacy benefit plan in a preferred provider organization. He is also using a root-cause analysis approach to evaluating medication errors in the community pharmacy setting.
- **Will Hollingworth** is conducting a controlled trial evaluating the effect of percutaneous vertebroplasty, and a controlled trial comparing different imaging techniques (CT-myelography vs. CT-MR) for viewing the cervical spine.
- **Srikanth Kadiyala** is continuing his work intended to determine the origin of racial disparities in health, and the impact of diffusion of information on cancer screening.
- **Todd Lee** is assessing adherence to antipsychotic regimens in patients with serious mental illness, and evaluating the risk of NSAID-related adverse events using clinical information.

- **Scott Ramsey** is evaluating treatment choice and quality of life for men with localized prostate cancer and he is conducting a prospective, controlled pragmatic trial of pegfilgratim delivered 'per protocol' vs. 'per usual care' for breast cancer. Together with Sean Sullivan, he is evaluating the use of colony stimulating factors in patients with breast and lung cancer.
- **Dave Smith** is studying the impact of prescribing safety alerts on potential medication error rates, conducting a randomized trial to measure the impact of several interventions on improving therapeutic monitoring in HMOs, and medication dosing errors in outpatient pediatric settings.
- **Andy Stergachis** is focusing on emergency preparedness for bioterrorism, including providing executive training for public health leaders, curriculum development for a Masters degree program in Strategic Planning for Critical Infrastructures, and assisting with Strategic National Stockpile activities at the state and local level.
- **Sean Sullivan** is the Core Director, Outcomes and Epidemiology Division of the UW Multidisciplinary Clinical Research Development Program (K-12). He continues his work in asthma, currently serving as an advisor to the Global Initiative for Asthma (GINA), Scientific Committee. With Dave Veenstra, he is implementing evidence-based assessments of laboratory-based diagnostic and genetic tests for health plan reimbursement.
- Using data from randomized controlled trials, **Dave Veenstra** is conducting a cost-effectiveness analysis and determining the feasibility of using patients' genetic information to help guide warfarin therapy, and conducting a cost-effectiveness analysis of entecavir vs. lamivudine for chronic hepatitis B infection.

#### Grants

**David Au**(PI) - Improving Health Outcomes for Patients with COPD, Department of Veterans Affairs

**David Au**(PI) -Improving the Quality of End-of-Life Communication for Patients with COPD, Department of Veterans Affairs

**David Au** (CoPI) - Quality of Practices of Lung Cancer, Department of Veteran Affairs

**Denise Boudreau** (PI) -Health Economic Burden of Metabolic Syndrome, The Medtap Institute

**Denise Boudreau** (PI) - Medications and Colorectal Cancer Risk, National Cancer Institute

**Denise Boudreau**(Co-PI) - Prescription Opioid Misuse in a Large HMO, National Institute on Drug Abuse

**Beth Devine** (PI) - Characterizing Medication Errors using an Ambulatory Computerized Prescriber Order Entry System, UW Royalty Research Fund

**Beth Devine** (PI) - Evaluating e-prescribing in a Community-based, Integrated Health System, Agency for Healthcare Research and Quality

**Beth Devine** (PI)- Surgical Site Infection Prevention: A Benchmarking Outcomes Study, Amerinet

**Jacqueline Gardner** (PI) - AMCP/University of Washington Management Development Program, Academy of Managed Care Pharmacy

**Jacqueline Gardner** (PI) - Improving Contraceptive Practice and Delivery through Community Pharmacies, National Institute of Child Health and Human Development

**Lou Garrison** (PI) - Assessing the Costs and Cost-Effectiveness of Capecitabine ("Xeloda®") in Adjuvant Chemotherapy for Dukes' C Colorectal Cancer, Hoffman-La Roche

**Lou Garrison**(PI)- Developing a Backgrounder for the Pharmaceutical and Biotech Industries on Pharmacogenetics/Genomics (PGx): From the Evolving Science to the Uncertain Future, PhRMA

**Lou Garrison** (PI) - Grant to PORPP to support research on personalized medicine, Hoffman-La Roche

**Will Hollingworth** (Co-I) - Sham-controlled trial of percutaneous vertebroplasty, National Institute of Arthritis and Musculoskeletal and Skin Diseases

**Will Hollingworth**(PI) - Spinal cord stimulators (SCS) for injured workers with chronic low back and leg pain after lumbar surgery, Washington State Department of Labor and Industries

**Todd Lee** (Co-I/Site PI) - Improving antipsychotic adherence among patients with serious mental illness, Veterans Administration Health Services Research & Development

**Todd Lee** (PI) - NSAID Related Adverse Events: Evaluating Risk Using Clinical Information, Veterans Administration Health Services Research & Development

**Todd Lee** (PI) - Outcomes assessment associated with salmeterol use in obstructive lung disease, Veterans Administration Health Services Research & Development

**Todd Lee** (PI) - Outcomes of COPD Management, Agency for Healthcare Research and Quality

**Scott Ramsey** (PI) - A Genetic Screening Policy Model for Colorectal Cancer, National Human Genome Research Institute

**Scott Ramsey** (PI) - A Retrospective Evaluation of Colony Stimulating Factor Use in Patients with Breast and Lung Cancer, Amgen, Inc. (Co-PI: **Sean Sullivan**)

**Scott Ramsey**(PI) - CanCORS: Lung/Colon Cancer Outcomes, Cancer Research Network

**Scott Ramsey** (PI) - Patterns of Second Line Chemotherapy Use and Direct Medical Costs for Persons with Non-Small Cell Lung Cancer, Genentech, Inc.

**Andy Stergachis (PI)** - Bioterrorism Curriculum Development Program, Health Resources & Services Administration (HRSA)

**Andy Stergachis (PI)** - Pandemic Influenza and Strategic National Stockpile/Cities Readiness Initiative Preparedness, Public Health-Seattle & King County

**Andy Stergachis (PI)** Pharmacovigilance Models for Pregnancy Malaria in Sub-Saharan Africa, Puget Sound Partnership for Global Health

**Sean Sullivan (PI)** - Defining value in health care for stakeholder segments, Johnson & Johnson

**Sean Sullivan (PI)** - Evaluating the Impact of an ACPOE/CDS System on Outcomes, Agency for Healthcare Research and Quality, (*Co-Is: Beth Devine, Will Hollingworth*)

**Sean Sullivan (Co-I)**- Improving CPP Management Information: Feedback and Nursing, National Institute of Nursing Research

**Sean Sullivan (PI)** - Template for and Application of Clinical and Economic Evaluation of Clinical Laboratory Testing Technologies, Labcorp, Inc. (*Co-I: Scott Ramsey*)

**David Veenstra (PI)** - An evidence-based cost-utility study of warfarin genotyping, Centers for Disease Control and Prevention

**David Veenstra (Co-I)** Center for Excellence in ELSI Research (CEER), Pharmacogenomics working group, NIH center grant

**David Veenstra (PI)** - The cost effectiveness of entecavir for the treatment of HBV infection, Bristol Meyers Squibb **David Veenstra (Co-PI)** - The economic implications of pharmacogenomics, Pharmaceutical Research and Manufacturers Association Foundation

## Special Services

### Health Economics and Outcomes Research Field-Based Training Programs

As an outgrowth of a brainstorming session at a recent meeting of the UW School of Pharmacy Corporate Advisory Board, PORPP initiated a program to train field-based, outcomes personnel employed in the pharmaceutical industry, in health economics and outcomes research. The Training Program is a two-day, fly-in (to Seattle) workshop delivered by members of the PORPP faculty to staff of a specific pharmaceutical company. The course has focused on providing education to the outcomes personnel who serve the managed care industry (field-based outcomes personnel). The coursework involves a mix of methods, application, and case studies, and is intended to provide these individuals with tools they can use to communicate effectively with their managed care customers. The course materials for each Training Program are developed in conjunction with the Head of the Health Outcomes unit at the respective firm, and are customized to the educational needs and the goals of the organizations. Programs have been conducted for Sanofi-Aventis, Amgen and Abbott Laboratories.

### Clinical Research Career Development Program

The K-12 Clinical Research Career Development Program is a newly launched program that involves a collaborative effort among all the health sciences schools and affiliated institutions. Funded by the NIH, the K-12 initiative is a program for doctoral level scholars from all the health professions. Selected participants will conduct intensively mentored research projects in one of the three designated program divisions: Translational Research, Clinical Trials, or Outcomes/Clinical Epidemiology/ Health Services Research. **Danny Shen** is Co-Director of the Translational Research Division; **Sean Sullivan** is Director of the Outcomes, Clinical Epidemiology, and Health Services Research Division. Young investigators will also receive rigorous instruction in clinical research methods, frequently while completing an MS degree from the School of Public Health or Pharmacy, in a Clinical Research Track.

### Grand Rounds Seminar Series

The Cost and Outcomes Grand Rounds Seminar Series was established by PORPP in 1997 to provide a forum for leading experts in cost and outcomes assessment to present clinical and economic research concepts and methods to University of Washington researchers and trainees, as well as members of the Seattle-area research, health insurance, pharmaceutical, biopharmaceutical and medical device industries.

The Cost and Outcomes Grand Rounds is jointly sponsored by the Pharmaceutical Outcomes Research and Policy Program, the UW Center for Cost and Outcomes Research, and the Outcomes Affinity Group at the Fred Hutchinson Cancer Research Center.

Our most recent guests included Adrian Towse, Director of the Health Economics Office, London; Jaime Caro, MD, Caro Research Institute, Boston, MA; and F. Reed Johnson, Ph.D., Sr. Fellow and Principal Economist, Research Triangle Institute.

### Corporate Advisory Board – Strategic Partnership

#### Members (2006)

**Don Buesching**, Eli Lilly  
**Anita Chawla**, PhD, Genentech, Inc.  
**Joe DiCesare**, Novartis (Chair – 2006)  
**Linda Harpole**, Glaxo SmithKline  
**Ansgar Hebborn**, Roche  
**Mitch Higashi**, MBA, PhD, GE Healthcare  
**Jeff Lee**, Allergan  
**Newell McElwee**, Pfizer  
**Josh Ofman**, MD, Amgen  
**Phillip Sarocco**, PhD, Boston Scientific  
**Vipan Sood**, RPh, MBA, MRPharmS, Organon, USA  
**Dave Sugano**, MPH, Schering-Plough (Chair – 2005)  
**Ray Townsend**, Elan  
**Todd Williamson**, Sanofi-Aventis  
**Ed Wong**, PharmD, Premera Blue Cross

With the help of our CAB members the PORPP faculty were able to assess our current levels of activity, and plan our future goals in the following areas:

- Train researchers who understand the perspective of, and are prepared to function at a high level within the pharmaceutical industry,
- Increase the number of PORPP graduates to fill available positions in the pharmaceutical industry,

- Develop the ability to respond to emerging industry research needs, both in terms of expertise of our graduates, and in terms of faculty to conduct research (e.g. quality of life and drug safety, respectively), and
- Train those currently employed in the industry setting, in the concepts of pharmacoeconomics and outcomes research.

### Selected Recent Publications

A systematic literature review of Magnetic Resonance Spectroscopy (MRS) for the characterization of brain tumors. **Hollingworth W**, Medina LS, Lenkinski RE, Shibata DK, Bernal B, Zurakowski D, et al. *AJNR* 2006 Aug;27(7):1404-11.

Benzodiazepine use and physical disability in community-dwelling older adults. **Gray SL**, LaCroix AZ, Hanlon JT, Penninx BW, **Blough DK**, Leveille SG, Artz MB, Guralnik JM, Buchner DM. *J Am Geriatr Soc.* 2006;54(2):224-30.

Breast Cancer in Limited-Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines. Anderson BO, Shyyan R, Eniu A, Smith RA, Yip C-H, Bese NS, Chow LWC, Masood S, **Ramsey SD**, **Carlson RW**. *The Breast Journal* 2006;12(Suppl. 1):S3-S15.

Breast Cancer in Limited-Resource Countries: Health Care Systems and Public Policy. Anderson BO, Yip C-H, **Ramsey SD**, Bengoa R, Braun S, Fitch M, Groot M, Sancho-Garnier H, Tsu VD, for the Global Health Care Systems and Public Policy Panel. *The Breast Journal* 2006;12(Suppl. 1):S54-S69.

Computerized prescribing alerts and group academic detailing to reduce the use of potentially inappropriate medications in the elderly. Simon SR, **Smith DH**, Feldstein AC, Perrin N, Yang X, Zhou Y, Platt R, Soumerai SB. *Journal of the American Geriatrics Society* 2006 Jun; 54(6):963-968.

Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer's disease [letter]. Bendar MM, **Lee TA**, Wolozin B, Weiss KB. *Neurology.* 2006; 66(11): 1785.

Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Weiss KB, Buxton M, Anderson FL, Lamm CJ, Liljas B, **Sullivan SD**. *Pediatric Allergy and Immunology* 2006;17(Suppl 17):21-27.

Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. **Sullivan SD**, Nutescu E, Kwong L. *Value in Health* 2006;9(2):68-76.

Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease. van der Palen J, Monninkhof E, van der Valk P, **Sullivan SD**, **Veenstra DL**. *Thorax.* 2006 Jan;61(1):29-33.

Differences in Health Care Utilization at the End-of-Life among patients with COPD and patients with lung cancer. **Au DH**, Udris EM, Fihn SD, McDonnell MB, Curtis JR. *Archives of Int Med* 2006 Feb 13;166(3):326-31.

Epidemiology and costs of chronic obstructive pulmonary disease. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS,

Thun MJ, Connell C, Jemel A, **Lee TA**, Miravittles M, Aldington S, Beasley R. *Eur Respir J.* 2006; 27(1): 188-207.

Impact of hormone therapy on false positive recall and costs among women undergoing screening mammography. **Boudreau DM**, Buist DSM, Rutter CM, Fishman, PA, Beverly KR, Taplin S. *Med Care.* 2006;44:62-69.

Implications of Part D for Mentally Ill Dual Eligibles: A Challenge for Medicare Morden NE and **Garrison LP**. *Health Affairs*, 25(2): 491-500, March-April 2006

Interrater Reliability in Assessing Quality of Diagnostic Accuracy Studies Using the QUADAS Tool A Preliminary Assessment. **Hollingworth W**, Medina LS, Lenkinski RE, et al. *Acad Radiol* 2006; 13:803-810.

Managing biotechnology in a network-model health plan: A US private payer perspective. Watkins JB, Roy Choudhury S, Wong E, **Sullivan SD**. *Health Affairs* 2006;25(5):1347-1352.

Pharmacoeconomic analysis of adjuvant oral capecitabine versus intravenous 5-FU-LV in Dukes' C colon cancer: the X-ACT trial Cassidy J, Douillard J-Y, Twelves C, McKendrick JJ, Scheithauer W, Bustova I, Johnston PG, Jelic S, Fountzilias G, Coxon F, Diao-Rubio E, Maughan TS Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, **Garrison LP**. *British J of Cancer*, 94(8):1122-1129, 2006

Post Exposure Prophylaxis with Oseltamivir: Cost Effectiveness and Cost Utility in Families in the U.K. Sander B, Hayden FG, Gyldmark M, and **Garrison LP**. *Pharmacoeconomics* 24(4): 373-386, 2006

Pretransplant Assessment of Mortality Risk after Allogeneic Hematopoietic Cell Transplantation. \*\*Parimon T, **Au DH**, Martin P, Chien JW. *Ann Int. Med.* 2006 Feb 13;166(3):326-31. \*\*\*(All authors contributed equally)

Prevention of deaths due to harmful drinking in the United States: the potential effects of tax increases and advertising bans on young drinkers. **Hollingworth W**, Ebel BE, McCarty CA, Garrison MM, Christakis DA, Rivara FP. *Journal of Studies on Alcohol* 2006 Mar;67(2):300-8.

Promoting the Pharmacist's Role in Public Health. **Stergachis A**. *J Am Pharm Assn.* 2006;46:311-14.

Reducing warfarin medication interactions: An interrupted time series evaluation. Feldstein A, **Smith DH**, Perrin N, Yang X, Simon SR, Krall MA, Sittig DF, Ditmer D, Platt R, Soumerai S. *Archives of Internal Medicine* 2006 May 8; 166(9):1009-1015.

Risk Factors for Statin-Associated Rhabdomyolysis. Schech S, Graham D, Staffa J, Andrade SE, Grenade LL, Burgess M, **Blough D**, **Stergachis A**, Chan KA, Platt R, Shatin D. *Pharmacoepidemiol Drug Saf.* 2006 Aug 7; [Epub ahead of print].

Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: A cost-effectiveness analysis. Meckley L, **Veenstra DL**. *Pharmacogenet Genomics* 2006;16:139-47.

Spirometry use in clinical practice following diagnosis of COPD. **Lee TA**, Bartle B, Weiss KB. *Chest.* 2006; 129(6): 1509-1515.

The ATTEMPT cohort: a multi-national longitudinal study of predictors, patterns and consequences of smoking cessation; introduction and evaluation of internet recruitment and data collection methods. West R, Gilsenan A, Coste F, Zhou X, Nonnemaker J, Curry SJ, **Sullivan SD**. *Addiction* 2006 Sep;101(9):1352-61.

The impact of prescribing safety alerts for the elderly in an electronic medical record: An interrupted time series evaluation. **Smith DH**, Perrin N, Feldstein A, Yang X, Kuang D, Simon SR, Sittig DF, Platt R, Soumerai S. *Archives of Internal Medicine* 2006 May 22; 166(10):1098-1104.

The influence of statin use on breast density. **Boudreau DM**, Rutter CM, Buist DSM. *Cancer Epidemiol Biomarkers Prev.* 2006 May;15(5):1026-1029.

The state of cost-effectiveness analysis in American managed care. Meenan RT, **Smith DH**, Hornbrook MC, Fellows J, Lynch FL, Helfand M. *Expert Review of Pharmacoeconomics and Outcomes Research* 2006; 6(2):229-237.

Toward evidence-based assessment of laboratory-based diagnostics and genetic test for health plan reimbursement. **Ramsey SD**, **Veenstra DL**, **Garrison LP**, **Carlson R**, Billings P, Carlson J, **Sullivan SD** *American Journal of Managed Care.* 12:197-202; April 2006.

Use of prescription medications with a potential for fetal harm among pregnant women. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, McPhillips H, Roblin D, **Smith DH**, Yood MU, Platt R, H Gurwitz J. *Pharmacoepidemiology and Drug Safety.* [Epub 2006 Apr 3].

Utility of Repeat Head Computed Tomography After Blunt Head Trauma: A Systematic Review. Wang MC, Linnau KF, Tirschwell DL, **Hollingworth W**. *Journal of Trauma* 2006 Jul;61(1):226-33.

What is the Most Cost-Effective Treatment for 1-2 Centimeter Bulbar Urethral Strictures: A Societal Approach Using Decision Analysis. Wright JL, Wessells H, Nathens AB, **Hollingworth W**. *Urology* 2006 May;67(5):889-93.

Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: A cost-effectiveness analysis. **Meckley L**, **Veenstra DL**. *Pharmacogenet Genomics* 2006;16:139-47.

The Cost-Effectiveness of Biologic Agents for the Treatment of AutoImmune Disorders: A Structured Review of the Literature. Fleurence RL, **Spackman DE**. Forthcoming in *The Journal of Rheumatology*. Nov. 2006.

### Gifts 2005-2006

PORPP would like to acknowledge our many supporters of this past year. Our accomplishments would not have been possible without these generous educational grants and gifts. We express our sincere gratitude to:

- Abbott Laboratories
- Academy of Managed Care Pharmacy
- Amgen
- Amerinet
- Beth Devine, PharmD, MBA
- J. Dunmore, PharmD

- Eli Lilly & Company
- Foundation for Managed Care Pharmacy
- Jacqueline Gardner, PhD
- Genentech
- Thomas Hazlet, PharmD, DrPH
- Mitchell Higashi, MBA, PhD
- Johnson & Johnson
- Douglas Kligman
- Todd Lee, PharmD, PhD
- Northwest Pharmacy Benefits & Medical Directors Group
- Novartis Pharmaceuticals
- PhRMA Foundation
- Putnam Associates
- Shelby Reed, PhD
- Roche Pharmaceuticals
- Sanofi-Aventis
- Sean Sullivan, PhD

### PORPP Faculty

**David Au**, MD, MPH, Affiliate Assistant Professor  
**Denise Boudreau**, PhD, Affiliate Assistant Professor  
**David Blough**, PhD, Research Associate Professor  
**Brian Custer**, PhD, Affiliate Assistant Professor  
**Emily Beth Devine**, PharmD, MBA  
 Research Assistant Professor and Associate Director,  
 Pharmaceutical Outcomes Research and Policy Program  
**D.S. (Pete) Fullerton**, PhD, Affiliate Professor  
**Jacqueline Gardner**, PhD, Professor  
**Lou Garrison**, PhD, Professor  
**Thomas Hazlet**, PharmD, DrPH, Associate Professor  
**Will Hollingworth**, PhD, Adjunct Research Assistant Professor  
**Eric Johnson**, MPH, PhD, Affiliate Assistant Professor  
**Srikanth Kadiyala**, MA, PhD, Assistant Professor  
**Todd Lee**, PharmD, PhD, Affiliate Assistant Professor  
**Malcolm Maclure**, PhD, Affiliate Associate Professor  
**Donald Patrick**, PhD, MSPH, Adjunct Professor  
**Scott Ramsey**, MD, PhD, Adjunct Professor, Director, Cancer Outcomes Research Program, Fred Hutchinson Cancer Research Center  
**David Smith**, RPh, MHA, PhD, Affiliate Assistant Professor  
**Andy Stergachis**, PhD, Adjunct Professor  
**Sean Sullivan**, PhD, Professor of Pharmacy, Medicine, and Public Health and Community Medicine; Director, Pharmaceutical Outcomes Research & Policy Program  
**David Veenstra**, PharmD, PhD, Associate Professor

**Pharmaceutical Outcomes Research and Policy Program**  
 Department of Pharmacy, University of Washington, Box 357630,  
 Seattle, WA 98195-7630  
 Phone: 206-616-1383, Fax: 206-543-3835  
 Email: porpp@u.washington.edu; URL:  
<http://depts.washington.edu/porpp>

**PORPP Administration**

**Sean D. Sullivan, PhD, Director**  
sdsull@u.washington.edu

**Beth Devine, PharmD, MBA, Associate Director**  
bdevine@u.washington.edu

**Penny L. Evans, Program Operations Specialist**  
pennye@u.washington.edu